Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Supplements & Reports
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
AstraZeneca's Recentin fails to show benefit over Roche's Avastin in Phase III colorectal cancer trial
Today
AstraZeneca is facing more disappointment with the development of its new anticancers after its experimental anti-angiogenic drug Recentin (cediranib) did not ...
GSK sees more value in licensing than AIDS patent pool
Today
GlaxoSmithKline, which has yet to decide on whether or not to participate in UNITAID 's AIDS medicines patent pool, sees more value in its own licensing ...
Ark withdraws EU brain cancer filing for Cerepro and starts strategic review
Today
Ark Therapeutics has withdrawn the EU filing of its brain cancer gene therapy candidate Cerepro (sitimagene ceradenovec), dropping a previous appeal over a ...
Genmab's zalutumumab fails Phase III trial in refractory head and neck cancer
Today
Genmab's experimental EGFR-targeted monoclonal antibody zalutumumab (HuMax-EGFr), one of its most advanced products in development, has failed to meet its ...
 
Lexicon plans to raise $95 million
Today
Lexicon Pharmaceuticals has announced plans to offer for sale $95 million of its common stock in an underwritten public offering. It could also sell up to $14.25 million worth of shares as an ...
Sanofi-Aventis, Merck and Lilly boost animal health businesses
Today
Sanofi-Aventis has exercised its option to combine its animal health business Merial with Intervet/Schering-Plough Animal Health , Merck & Co 's animal health unit. Sanofi-Aventis bought out Merck's ...
Vernalis pays $33 million to regain frovatriptan royalty rights
Today
The UK firm Vernalis has regained full rights to the royalties on its only marketed product, the migraine treatment frovatriptan. It made a one-off net cash payment of $32.57 million to Paul Capital ...
Polpharma buys Bioton's antibiotics business
Today
Polpharma, one of Poland's largest pharmaceutical manufacturers, is buying an antibiotics production business from Bioton , another local company, for PLN 80 million ($8 million). Poland's office of ...
 
Antidiabetic GLP-1s only linked to thyroid cancer in rodents, study suggests
05 March 2010
Thyroid cancer risks of anti-diabetic GLP-1 analogues are probably limited to rats and mice, suggests Novo Nordisk -sponsored research published this week in the journal Endocrinology. Investors, who ...
Lundbeck sees hope in re-analysis of failed Phase III desmoteplase stroke trial
05 March 2010
A post-hoc analysis of the failed DIAS-2 Phase III study of Lundbeck 's candidate for the treatment of ischaemic stroke, desmoteplase, suggests that the drug is effective in the sub-group of patients ...
Takeda and Lundbeck lay out Phase III plans under depression alliance
05 March 2010
Takeda and Lundbeck have unveiled details of new pivotal Phase III programmes for two novel molecules for major depressive disorder (MDD) being co-developed under their 2007 alliance for mood and ...
US FDA allows Synta to resume development of anticancer elesclomol
03 March 2010
Synta Pharmaceuticals has received the go-ahead from the US FDA to resume development of its novel anticancer elesclomol, an oxidative stress inducer whose closely watched Phase III trial in ...
 
Slovak pharma multinationals' association elects new board
Today
Slovakia’s association of research-based pharmaceutical companies (SAFS) has elected a new board. Dr Pavol Trnovec of GlaxoSmithKline, who was previously its vice-chairman, will lead SAFS as ...
FDA: final guidance on developing cell-based viral vaccines
Today
The US FDA recognises emerging and pandemic threats – and it aims to boost the development of cell-based viral vaccines with the publication of a final guidance entitled Guidance for Industry: ...
Philippines makes more medicine price cuts for pharma
Today
The Philippines government has announced a second wave of price cuts in the medicines sector under the government-mediated access price (GMAP) programme. Most reductions will come into effect on ...
Brazil increases import tariffs on some US medicines
Today
Brazil's chamber for foreign trade, CAMEX, has published a list of 100 products coming from the US that will be subject to higher import duties following a WTO dispute over cotton subsidies. The list ...
 
PEOPLE
Board changes at Cytos Biotechnology Cytos Biotechnology (Switzerland) has elected its vice-chairman, Dr Thomas Hecht , to succeed Dr ...
New board appointment at Orexigen Orexigen Therapeutics, a US biopharmaceutical company focused on the treatment of obesity, has ...
New appointment at Catalyst Biosciences Catalyst Biosciences , a US company focused on the discovery and development of engineered ...
>> More People News...

EXPERT VIEW
Nurturing innovation through mergers – by Fred Hassan
08 March 2010
Fred Hassan
Following the latest round of pharma mergers and as a long-time participant in this ...

Market Insight: Big pharma hit by Greece's fiscal crisis
Today

Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of ...

 Market Insight - Fear gives way to prudence a...

How to run clinical trials in the Middle East - why the GCC?
04 March 2010

A grouping of Middle Eastern countries came together under the auspices of the Gulf Co-operation ...

How to run clinical trials in the Middle East - Jordan
04 March 2010

Jordan has a population of 6.35 million and its GDP per capita is $5,000, while its healthcare ...

MULTIMEDIA
Scrip in a minute - week ending March 5th 05 March 2010

Get the Flash Player to see this player.

Genzyme's gambit: A hedge against Carl Icahn
18 February 2010
Christopher Spillane
The fall in Genzyme 's share price made it an obvious target. The Massachusetts based biotech ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Face to Face with Sandoz's "growth guy" Jeff George
04 March 2010
Eleanor Malone
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big ...

CPhI Worldwide 2009
13 October 2009
Scrip's official preview of CPhI Worldwide, ICSE, P-MEC and BioPh 2009

Scrip's Stock Tracker: January 2010
10 February 2010
Ashley Yeo
Fears that a market correction was imminent pushed the equity markets down as January tapered out, ...

EVENTS
11 March 2010
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm